CAR T Cell Trafficking to Tumor Tissue
Track CAR T cell movement and engagement in real-time
- Starting in blood vessels and ending in target tissues, we quantify circulation through the blood vessel, activation of endothelium, extravasation, migration through the extracellular matrix, and killing of the target expressing tumor cells over time.
- Real-time visualization also provides potential differences between target and non-target cell interactions. This provides critical information on the targeting accuracy and efficiency of various CAR T constructs.
- Cytokine release provides insight into T cell-mediated killing and the influence of the tumor microenvironment.
CAR T cell migration towards non-target and target cells in presence of CXCL12
Solid Tumor Killing by CAR T Cells
Assess Tumor-Killing Potential
- Evaluation of CAR T cell efficacy and effector-to-target ratios.
- Assessment of the efficacy of different CAR T variants.
- Working with multiple donors provides insight in heterogeneity of tumors between patients.
- Working with patient derived material we capture target heterogeneity within the tumor.
Tumor cell death upon CAR T treatment
Comparison and Ranking of CAR T Cell Constructs Based on Killing Efficacy
Our platform facilitates:
- Comparing and ranking CAR T constructs based on their tumor-killing efficacy, including variations such as CD28 or 4-1BB co-stimulatory domains.
- Combination therapy enhancing CAR T performance.
- Studying CAR T-associated toxicity and/or on-target off tumor toxicity to the blood vessel or other organ cells.
Tumor area response by construct type, detailing the higher efficacy observed with different co-stimulatory domains.
